NHS Brain Tumour Genomic Test Rolled Out in Newcastle 2026

Key Points

• The Newcastle Hospitals NHS Foundation Trust, together with Newcastle University is one of the five special NHS centers in England implementing the new rapid genomic test pilot project for brain tumors.
• This diagnostic technology quickly examines the genetic information of the tumor, reducing the diagnosis time from several weeks to just a few days or even less than two hours during surgery.
• The pilot is being carried out with the support of an NHS England program spanning two years aimed at determining whether intraoperative rapid genomic analysis is feasible for implementation in the NHS.
• Quick identification allows starting chemotherapy and radiotherapy targeting earlier without patients having to wait in diagnostic limbo.
• The pilot is being launched in Nottingham, Birmingham, London, and Newcastle and will be extended to Bristol, Oxford, Leeds, and Manchester.

Newcastle (Newcastle Times) September 25, 2026 – A pioneering rapid genomic test currently trialled across select NHS trusts, including Newcastle Hospitals NHS Foundation Trust in partnership with Newcastle University, could fundamentally transform the speed and accuracy of brain tumour diagnoses in England. The novel technology analyses small tumour samples to deliver comprehensive genetic classifications in days, or within two hours during active surgery, sharply reducing traditional lab turnaround times that often stretch across multiple weeks.

What Is the New NHS Rapid Brain Tumour Test?

As detailed by clinical scientist Angharad Goodman of Newcastle Hospitals NHS Foundation Trust, the breakthrough relies on rapid genomic sequencing to decode a tumour sample’s genetic makeup. Rather than relying solely on conventional microscopic examination and lab cultures that require weeks, the genomic test maps the unique biological profile of the tissue quickly.

Goodman, who serves as project lead, described the trial as “really exciting” and emphasized that

“the test could revolutionise brain tumour diagnosis”.

She stated:

“This new single test could give us all the information that we require for brain tumour diagnosis within days”.

Goodman further added:

“The aspiration is to have a provisional result while the patient is still in surgery, which would be amazing, and would build on the work already demonstrated through the national pilot programme”.

Why Is Rapid Diagnosis Critical for Brain Tumour Patients?

Primary brain tumours affect over 12,000 individuals across the UK each year and remain the leading cancer killer among children and adults under the age of 40. Because there are around 150 distinct types of brain tumours—ranging from slow-growing low-grade lesions to aggressive high-grade malignancies—identifying the exact molecular subtype is vital for picking the correct treatment regimen.

As reported by health correspondents covering NHS England developments, Professor Simon Bailey, consultant paediatric oncologist at the Great North Children’s Hospital, highlighted the direct impact on young patients. Bailey stated that the technology would

“significantly improve our ability to make a rapid and accurate diagnosis”.

He noted that this precision would yield

“faster treatment planning so that children can start the most effective treatment as soon as possible,”

while offering crucial clarity:

“It will also allow clarity for children and their families much sooner so they can plan their lives”.

Explore More Local Newcastle News

Newcastle Chronicle Shares Photos of Students During Freshers Week Newcastle 2026

Anant Ambani Appointed Newcastle Sustainability Professor in Newcastle Upon Tyne 2026

How Does Newcastle University Support the Genomic Pilot?

The trial in Newcastle brings together a multidisciplinary clinical team, pairing NHS hospital specialists in genetics, oncology, neurology, and histopathology with scientists at Newcastle University’s Genomics Core Facility.

Dr Jonathan Coxhead, head of the Genomics Core Facility at Newcastle University, described the collaboration as “fantastic”. Coxhead remarked that it was

“exciting knowing this can have a direct impact on improving patient care.”

Which Hospitals Are Participating in the National Rollout?

Funded as part of a two-year evaluation pilot by NHS England, the scheme is testing whether rapid sequencing can be successfully embedded into standard neuro-oncological pathways across the country.

Background of the Development

Traditionally, diagnosing brain cancer requires a combination of neuroimaging (such as MRI or CT scans) and surgical extraction of tissue. Once excised, pathology laboratories process tissue samples through formal chemical staining and microscopic evaluation. While accurate, processing complex molecular markers routinely takes anywhere from two to four weeks.

To address these delays, researchers at the University of Nottingham and Nottingham University Hospitals NHS Trust adapted Oxford Nanopore sequencing technology for rapid neuropathology. By passing DNA strands through microscopic pores and measuring current alterations, custom algorithms read a tumour’s genetic fingerprint in real time. Early trials demonstrated that over 90% of tested samples yielded initial molecular classifications within two hours. NHS England subsequently established the Brain Cancer NHS Genomic Network of Excellence to scale this research into clinical hospital settings.

Predictions: How Will This Development Affect Patients and Clinical Care?

1. Enhanced Surgical Precision

Receiving genetic classifications while an operation is actively underway gives neurosurgeons immediate insight into tumour aggressiveness. This real-time guidance helps surgical teams safely maximize tumour resection while protecting surrounding healthy brain tissue.

2. Accelerated Start of Targeted Therapies

Shortening the diagnostic turnaround to a few days allows oncology teams to prescribe precise radiotherapy, chemotherapy, or targeted biological agents much sooner. Early intervention prevents aggressive tumours from advancing untreated during traditional multi-week waiting periods.

3. Expanded Access to Precision Clinical Trials

Many modern clinical trials require specific genetic mutations or biomarkers for patient eligibility. Ultra-rapid profiling allows patients to meet narrow enrollment windows for cutting-edge experimental therapies before standard treatments alter their profile.

4. Reduced Psychological Burden on Families

Waiting weeks for a definitive cancer diagnosis inflicts intense psychological stress on patients and their families. Replacing uncertainty with rapid diagnostic clarity allows families to make informed care choices and plan their lives without prolonged agonizing delays.